{"slideshow_credits": null, "snippet": "A panel of experts said tamoxifen and raloxifene may be worth taking to lower the risk of breast cancer despite the potential for serious side effects like blood clots and strokes.", "abstract": "Influential panel of experts says breast cancer drugs tamoxifen and raloxifene may be worth taking for healthy higher-risk women, despite potential for serious side effects like blood clots and strokes.", "section_name": "Health", "print_page": "16", "document_type": "article", "byline": {"person": [{"firstname": "Denise", "role": "reported", "lastname": "GRADY", "rank": 1, "organization": ""}], "original": "By DENISE GRADY", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/04/16/health/breast-cancer-drugs-urged-for-healthy-high-risk-women.html", "lead_paragraph": "A panel of experts said tamoxifen and raloxifene may be worth taking to lower the risk of breast cancer despite the potential for serious side effects like blood clots and strokes.", "headline": {"seo": "Breast Cancer Drugs Urged for Healthy High-Risk Women", "main": "Breast Cancer Drugs Urged for Healthy High-Risk Women", "print_headline": "Panel\u2019s Report Urges Breast Cancer Drugs for Healthy Higher-Risk Women"}, "_id": "516c6a7ccf28d02a610009b3", "word_count": "1100", "multimedia": [], "pub_date": "2013-04-16T00:00:00Z", "source": "The New York Times", "news_desk": "National", "keywords": [{"value": "Breast Cancer", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Tamoxifen (Drug)", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "United States Preventive Services Task Force", "name": "organizations", "is_major": "N", "rank": "3"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}